New syringe for eye disease injections passes usability test
NCT ID NCT07501052
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether doctors could safely and correctly use a new prefilled syringe (SCD411) for eye injections. It included 33 adults with wet age-related macular degeneration, retinal vein occlusion, diabetic macular edema, or diabetic retinopathy. The main goal was to see if doctors could complete tasks like opening, injecting, and disposing of the syringe without errors. This was not a treatment study—it focused on how easy and safe the device is to use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Retina and Macular Disease
Winter Haven, Florida, 33880, United States
-
East Florida Eye Institute
Stuart, Florida, 34994, United States
-
Retina Vitreous Surgeons of Central New York, PC
Liverpool, New York, 13088, United States
-
University Retina & Macula Associates, P.C
Lemont, Illinois, 60439, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could eye drops replace injections for a leading cause of blindness?
- Could a daily eye gel replace injections for wet AMD?
- AI eye doctor: could software catch diabetic blindness sooner?
- Can a new eye injection preserve vision in south asians with diabetes?
- Can eye scans reveal hidden clues about diabetes damage?
- Could a biosimilar eye injection offer a new way to treat diabetic macular edema?